Evgen Pharma PLC (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the publication in a peer reviewed scientific
Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will hold its Annual General Meeting this afternoon in Manchester. At
Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks through the Preliminary Results Presentation for the year ended 31 March 2017. Evgen Pharma Plc is a clinical stage drug development
Evgen Pharma Plc (LON:EVG) is a virtual pharmaceutical company focused on the development of a synthetic version of a natural product, sulforaphane, which is known to modulate key signalling pathways
Evgen Pharma’s Dr Stephen Franklin discusses their final results for year-ended 31st March 2017 in this exclusive interview with DirectorsTalk
Evgen Pharma Plc (LON:EVG) CEO Dr Stephen Franklin talks to DirectorsTalk about its final results for the year ended 31 March 2017. Stephen reminds us of who Evgen Pharma are
Dr Stephen Franklin, Chief Executive Officer of Evgen Pharma LON:EVG, said: “We are very pleased to have progressed our SFX-01 product candidate into two phase II clinical trials: in breast
Evgen Pharma Plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has today announced an update on its two Phase II clinical
Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March
Dr Stephen Franklin, Founder and CEO of Evgen Pharma plc, said: “We are delighted to have found a flexible way to access specialist technical expertise and operational support to complement
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
